ZMYM2 and acute lymphoblastic leukemia: To determine whether IRAK1 has a broader influence on different leukemia subtypes, we used CRISPR/Cas9 to knock out IRAK1 in ZMYM2-FGFR1 expressing ZNF112 cells [4], which predominantly show a T-cell ALL immunophenotype.